Abstract：
BACKGROUND: Enzalutamide is an androgen receptor inhibitor and is used in metastatic castration-resistant prostate cancer. Seizure is a rare side effect of enzalutamide. In this case, the patient had an epileptic seizure while on enzalutamide treatment. His treatment management and and use of enzalutamide afterwards is discussed.
METHODS: A 78-year-old male patient who received previous treatments for metastatic castration-resistant prostate cancer was started on enzalutamide due to progression, and had an epileptic seizure while taking enzalutamide was presented. Different pathologies such as the use of other drugs, brain metastasis, bleeding, electrolyte, liver and kidney disorders that can cause epileptic seizures were explored and not found to be the cause in this patient. No neurological pathology was found in the patient after the seizure.
METHODS: Enzalutamide and antiepileptic treatment were initiated simultaneously again in the patient whose treatment was interrupted after the seizure and no pathology was found in the brain magnetic resonance imaging. Under this dual treatment, the patient did not have seizures again.
CONCLUSIONS: Although observed rarely, enzalutamide-induced epileptic seizure is a known side effect. However, a review of literature did not reveal any report on patients for whom enzalutamide and antiepileptic treatment were initiated and followed up simultaneously after seizures. This case report will contribute to the literature for patients whose treatment options have been exhausted and who may benefit significantly from continued use of enzalutamide despite having a seizure.
METHODS: A 78-year-old male patient who received previous treatments for metastatic castration-resistant prostate cancer was started on enzalutamide due to progression, and had an epileptic seizure while taking enzalutamide was presented. Different pathologies such as the use of other drugs, brain metastasis, bleeding, electrolyte, liver and kidney disorders that can cause epileptic seizures were explored and not found to be the cause in this patient. No neurological pathology was found in the patient after the seizure.
METHODS: Enzalutamide and antiepileptic treatment were initiated simultaneously again in the patient whose treatment was interrupted after the seizure and no pathology was found in the brain magnetic resonance imaging. Under this dual treatment, the patient did not have seizures again.
CONCLUSIONS: Although observed rarely, enzalutamide-induced epileptic seizure is a known side effect. However, a review of literature did not reveal any report on patients for whom enzalutamide and antiepileptic treatment were initiated and followed up simultaneously after seizures. This case report will contribute to the literature for patients whose treatment options have been exhausted and who may benefit significantly from continued use of enzalutamide despite having a seizure.
摘要：
背景：恩扎鲁胺是一种雄激素受体抑制剂，用于转移性去势抵抗性前列腺癌。癫痫发作是恩杂鲁胺的罕见副作用。在这种情况下,患者在接受恩杂鲁胺治疗时出现癫痫发作.讨论了他的治疗管理和随后使用恩杂鲁胺。
方法：一名78岁男性患者因进展而开始服用恩杂鲁胺，此前曾接受过转移性去势抵抗性前列腺癌的治疗，服用恩扎鲁他胺时癫痫发作。不同的病理，如使用其他药物，脑转移瘤,出血,电解质,研究了可能导致癫痫发作的肝脏和肾脏疾病，但未发现是该患者的原因。癫痫发作后，患者未发现神经系统病理。
方法：在癫痫发作后中断治疗且在脑磁共振成像中未发现病理的患者中，再次同时开始恩扎鲁胺和抗癫痫治疗。在这种双重治疗下，患者没有再次发作。
结论：尽管很少观察到，恩杂鲁胺诱导的癫痫发作是已知的副作用。然而,文献综述没有发现任何关于癫痫发作后开始恩杂鲁胺和抗癫痫治疗并同时随访的患者的报道.该病例报告将为治疗方案已经用尽的患者提供文献，这些患者尽管有癫痫发作，但仍可能从继续使用恩杂鲁胺中获益。
方法：一名78岁男性患者因进展而开始服用恩杂鲁胺，此前曾接受过转移性去势抵抗性前列腺癌的治疗，服用恩扎鲁他胺时癫痫发作。不同的病理，如使用其他药物，脑转移瘤,出血,电解质,研究了可能导致癫痫发作的肝脏和肾脏疾病，但未发现是该患者的原因。癫痫发作后，患者未发现神经系统病理。
方法：在癫痫发作后中断治疗且在脑磁共振成像中未发现病理的患者中，再次同时开始恩扎鲁胺和抗癫痫治疗。在这种双重治疗下，患者没有再次发作。
结论：尽管很少观察到，恩杂鲁胺诱导的癫痫发作是已知的副作用。然而,文献综述没有发现任何关于癫痫发作后开始恩杂鲁胺和抗癫痫治疗并同时随访的患者的报道.该病例报告将为治疗方案已经用尽的患者提供文献，这些患者尽管有癫痫发作，但仍可能从继续使用恩杂鲁胺中获益。
